This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
by Zacks Equity Research
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
INGNPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
by Zacks Equity Research
JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.
JNJPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?
by Moumi Mondal
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
STEPositive Net Change SYKPositive Net Change EWNegative Net Change
medical medical-devices
Is it the Right Time to Retain DGX Stock in Your Portfolio?
by Zacks Equity Research
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
DGXPositive Net Change TFXPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?
by Zacks Equity Research
Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.
INSPPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?
by Zacks Equity Research
BTSG's nearly 59% YTD surge is backed by 23% revenue growth, rising margins and expansion in specialty pharmacy and home-based care.
BTSGNegative Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
SYKPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally?
by Zacks Equity Research
Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.
HIMSPositive Net Change GDRXNegative Net Change DOCSNegative Net Change TEMPositive Net Change
medical medical-devices
Should You Buy Five Below (FIVE) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
FIVEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Accelerant Holdings (ARX)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ARXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines